From the CEO

At Novavax, we’ve brought together state-of-the-art science, cutting-edge manufacturing techniques, and passionate, talented professionals to create the vaccines of tomorrow. In light of today’s critical health concerns, we aim to provide real solutions through rapid vaccine production worldwide. We believe that halting the spread of contagious diseases is possible through innovation and perseverance.

— Stanley C. Erck, President & CEO

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant protein nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases. Novavax is involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India, LG Life Sciences of Korea, PATH and recently acquired Isconova AB, a leading vaccine adjuvant company located in Sweden. Together, Novavax' network supports its global commercialization strategy to create real and lasting change in the biopharmaceutical and vaccinology fields. Additional information about Novavax is available on the company's website,

Click here for Webcast

13th Annual Needham Healthcare Conference
April 9, 2014, 12:10 pm ET


These next-generation flu vaccines hold the potential to be even more effective and to make the first and last doses of vaccine available sooner than existing flu vaccines by weeks and months which can save lives during a pandemic as well as during seasonal flu outbreaks. (more info)

— Kathleen Sebelius, Secretary, U.S. Department of Health & Human Services